|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A clonal IDH1 R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent tumour.
|
25732040 |
2015 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 15.3% of enrolled GBMs demonstrated loss of ATRX expression (ATRX-), 10.4% expressed an aberrant IDH1 R132H protein (IDH1+), and 48.4% exhibited p53 overexpression (p53+).
|
27478330 |
2016 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among the GBM cases it was noted that the IDH1 immunopositive tumors (R132H mutant protein; n=17) had a low MnSOD expression as opposed to IDH1 immunonegative tumors (n=106), which had high expression of MnSOD (p=0.0307).
|
26616112 |
2016 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
|
23011765 |
2013 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For this reason, it was suggested that immunohistochemistry against IDH1 R132H is sufficient to classify GBM as IDH wild-type in this age group.
|
31758617 |
2020 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we show that SREBPs were up-regulated in U87 human glioblastoma cells transfected with an IDH1(R132H)-expression plasmid.
|
24077277 |
2013 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HMab-2 detected endogenous IDH1-R132H protein expressed in glioblastoma in immunohistochemical analysis.
|
26381180 |
2015 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition to the previously reported p.R132H and p.R132S alleles, we identified three novel somatic mutations (p.R132C, p.R132G, and p.R132L) affecting residue IDH1(R132) in GBM.
|
19117336 |
2009 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, overexpression of IDH1-R132H in glioblastoma cell lines U87 and U251 led to reduced cell proliferation, migration and invasion, accompanied by increased apoptosis.
|
26860959 |
2016 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we investigated which genes are differentially regulated in IDH1 wild type (IDH1WT) or IDH1 R132H mutation (IDH1R132H) glioblastoma cells.
|
28445981 |
2017 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Induction of G-CIMP+ state by exogenous expression of a mutated isocitrate dehydrogenase 1, IDH1-R132H, suppressed EGFR and H-Ras protein expression as well as pERK accumulation in independent glioblastoma models.
|
25277177 |
2014 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07).
|
29404978 |
2018 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate analysis revealed age, Karnofsky performance score, extent of tumor resection, first-line treatment, year of diagnosis, and MGMT promoter methylation status were associated with survival in patients with IDH1(R132H) -nonmutant glioblastoma.
|
27088883 |
2016 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results indicate that the IDH1 R132H mutation is a powerful prognostic marker in GBM treated with chemoradiation.
|
20560678 |
2010 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overexpression of IDH1(R132H) and IDH2(R172K) mutant protein in glioblastoma cells resulted in increased radiation sensitivity and altered ROS metabolism and suppression of growth and migration in vitro.
|
23115158 |
2013 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The R132H mutation in isocitrate dehydrogenase 1 (IDH1<sup>R132H</sup>) is commonly observed and associated with better survival in glioblastoma multiforme (GBM), a malignant brain tumor.
|
31151327 |
2019 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this study was to explore the difference in high mobility group A1 (HMGA1) expression and isocitrate dehydrogenase (IDH) 1 R132H point mutation in initial and recurrent glioblastoma multiforme (GBM), and to further identify whether the expression of HMGA1 has a role in the malignant progression of GBM.
|
26092597 |
2015 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1α expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment.
|
29625108 |
2018 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The prognostic value of IDH1 R132H mutation in GBM patients was verified.
|
24511544 |
2014 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This group showed absent IDH1-R132</span>H expression, which is characteristic of primary GBM.
|
22197544 |
2012 |
|
rs121913500
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma.
|
26757882 |
2016 |